AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00891228 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nestorone®
Description: Nestorone® Gel will be delivered by a pump configured to deliver a metered volume of Nestorone® Gel containing 12 mg of Nestorone®. For 12 mg Nestorone® dose; Nestorone® Gel will be delivered in 4 mL volume (3 mg Nestorone®/mL gel) by pressing two times with 2 mL dispenser head.
Study NCT00891228 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Nestorone®
Description: Nestorone® Gel will be delivered by a pump configured to deliver 4 mL of gel containing 0 mg of Nestorone® by pressing two times with the 2 mL dispenser head.
Study NCT00904488 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Addition of oral Metolazone
Description: Addition of oral metolazone 5 mg daily to continued current dose of intravenous bolus furosemide
Study NCT00904488 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Furosemide dose escalation
Description: Furosemide dose escalation via either IV bolus (2-2.5 x current dose) or continuous infusion (2-2.5 x current dose administered over previous 24 hours)
Study NCT03415945 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cardiac resynchronization therapy (CRT)
Description: All study participants have a clinical indication for CRT and will receive CRT implantation as part of their routine medical care. Additionally, participants will receive temporary left and right ventricular septal pacing electrodes and a temporary PressureWire to investigate the acute hemodynamic effect of left ventricular septal pacing, using patients as their own controls.
Study NCT01599013 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Vinflunine, Gemcitabine
Description: * Vinflunine 280 or 250 mg/m2, IV administration over 20 minutes (starting dose based on baseline creatinine clearance value), Day 1 every 3 weeks up to progression or unacceptable toxicity or patient's refusal~* Gemcitabine 750 or 1000 mg/m2, IV administration over 30 minutes (starting dose based on baseline creatinine clearance value), Day 1 and 8 every 3 weeks up to progression or unacceptable toxicity or patient's refusal
Study NCT01599013 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Vinflunine, Carboplatin
Description: * Vinflunine 280 or 250 mg/m2, IV administration over 20 minutes (starting dose based on baseline creatinine clearance value), Day 1 every 3 weeks up to progression or unacceptable toxicity or patient's refusal~* Carboplatin AUC 4.5, IV administration over 60 minutes, Day 1 every 3 weeks up to progression or unacceptable toxicity or patient's refusal
Study NCT02445326 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Study NCT02445326 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Vehicle
Study NCT01880359 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT04156815 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral isotretinoin
Description: Oral isotretinoin has remained the most effective medication for moderate-to-severe AV.Subjects received oral isotretinoin (Xingyi Yan'an Pharmaceutical, Shanghai, China) (1mg/kg/d for the first 2-4 weeks and 0.5mg/kg/d for the next 12-14 weeks) for a total of 16 weeks. Serum triglycerides, cholesterol and levels of liver enzymes were monitored every month during oral isotretinoin medication.
Study NCT00567359 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib
Description: Oral drug taken daily around the same time. Starting dose is 150mg once daily.
Study NCT03470207 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Post-pulmonary embolism follow up protocol
Description: Structured post-pulmonary embolism follow up protocol (outlined in Aim 1)
Study NCT04156815 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral isotretinoin
Description: Oral isotretinoin has remained the most effective medication for moderate-to-severe AV.Subjects received oral isotretinoin (Xingyi Yan'an Pharmaceutical, Shanghai, China) (1mg/kg/d for the first 2-4 weeks and 0.5mg/kg/d for the next 12-14 weeks) for a total of 16 weeks. Serum triglycerides, cholesterol and levels of liver enzymes were monitored every month during oral isotretinoin medication.
Study NCT04156815 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pricking blood therapy
Description: Pricking blood therapy (PBT) is a modified acupuncture strategy that is adapted to treat inflammatory related diseases. It has been shown to be effective in treatment of many chronic and acute inflammatory conditions including vasomotor rhinitis, acute herpes zoster and acute gouty arthritis,suggesting a potential efficacy for AV as well. At the end point of each session of laser treatment, an acupuncture practitioner performed a PBT in the areas within 1.5 cm radius of the five facial acupoints (Yintang, Zhukong, Sun, Yingxiang, Cuanzhu) (Figure 1). These areas usually appeared intensive erythema. A facial sheet mask was used to clean the face after PBT, and the face was cooled by air cooler for 10 minutes.
Study NCT04434131 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Convalescent Plasma
Description: Study subjects will receive 1 unit (200mL) of SARS-CoV-2 convalescent plasma collected from a single donor who recovered from COVID-19.
Study NCT01870115 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Fiber Pill
Description: This fiber pill has been manufactured to mimic the pill that contains the dietary supplements melatonin (M), strontium citrate (S), vitamin D3 (D) and vitamin K2 (K) in appearance but does not contain the supplements
Study NCT01870115 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Melatonin, Strontium citrate, Vitamins D3 and K2
Description: Each pill has been manufactured to contain the dietary supplements 2.5mg melatonin (M), 225mg strontium citrate (S), 1000IU vitamin D3 (D) and 30mcg vitamin K2 (K)
Study NCT02352623 — intervention group
Intervention type: RADIATION
Intervention: DXA scan
Description: DXA scan
Study NCT02352623 — intervention group
Intervention type: PROCEDURE
Intervention: Clinical examination
Description: Clinical examination
Study NCT02533492 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: vicryl
Description: wound closure with vicryl suture
Study NCT02533492 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vicryl plus
Description: wound closure with vicryl plus suture
Study NCT03058055 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo group will have unstructured lifestyle activities (normal lifestyle activities without restraint).
Study NCT03058055 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Origami
Description: Origami lessons (one hour/week) with daily take home Origami activities to complete
Study NCT03058055 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Reading
Description: Book club that includes weekly one hour meetings and daily reading assignments
Study NCT03376737 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib
Description: Apatinib (250 mg/d) + Pemetrexed (500 mg/m2)
Study NCT02828436 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Precision Spectra System
Description: Spinal Cord Stimulation
Study NCT02828436 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Exercise Intervention
Description: Standard Exercise
Study NCT01247168 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD2461
Description: oral capsules, continuous dosing and intermittent dosing
Study NCT01510158 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lesinurad
Description: Tablets, 200 mg once daily (qd)
Study NCT01510158 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lesinurad
Description: Tablets, 400 mg qd
Study NCT01510158 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tablets, Placebo qd
Study NCT01510158 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Allopurinol
Description: Tablets, ≥ 300 mg QD (≥ 200 mg qd for subjects with moderate renal impairment)
Study NCT01510158 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Allopurinol
Description: Tablets, ≥ 300 mg QD (≥ 200 mg qd for subjects with moderate renal impairment)
Study NCT00738751 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Panobinostat (LBH589)
Description: Panobinostat was taken twice weekly, for 2 out of 3 weeks of each cycle. Each cycle was defined as a 21-day period. Four dose levels of panobinostat in combination with erlotinib were planned: 1) dose level 1 (DL1) = panobinostat 20 mg by mouth (PO) twice weekly for 2 out of 3 weeks + erlotinib 100 mg PO daily; 2) dose level 2 (DL2) = panobinostat 30 mg and erlotinib 100 mg; 3) dose level 3 (DL3) = panobinostat 30 mg and erlotinib 150 mg; and 4) dose level 4 (DL4) = panobinostat 40 mg and erlotinib 150 mg. Doses were not escalated over the course of treatment of an individual participant.
Study NCT00738751 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: erlotinib
Description: Erlotinib was taken daily without interruption. Each cycle was defined as a 21-day period. Panobinostat was taken twice weekly, for 2 out of 3 weeks of each cycle. Four dose levels of panobinostat in combination with erlotinib were planned: 1) dose level 1 (DL1) = panobinostat 20 mg by mouth (PO) twice weekly for 2 out of 3 weeks + erlotinib 100 mg PO daily; 2) dose level 2 (DL2) = panobinostat 30 mg and erlotinib 100 mg; 3) dose level 3 (DL3) = panobinostat 30 mg and erlotinib 150 mg; and 4) dose level 4 (DL4) = panobinostat 40 mg and erlotinib 150 mg. Doses were not escalated over the course of treatment of an individual participant.
Study NCT02210858 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT02210858 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tipifarnib
Description: Given PO
Study NCT03871244 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Less red blood cell transfusions
Description: The instructions given to caregivers will be to consider prescribing a red blood cell transfusion only if the hemoglobin level is ≤ 70 g per L.
Study NCT03871244 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: More red blood cell transfusion (standard transfusion strategy in PICU)
Description: The instructions given to caregivers will be to prescribe a red blood cell transfusion according to their usual standard practice
Study NCT00536471 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Duloxetine hydrochloride
Study NCT02147041 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01880359 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nimorazole
Study NCT02990845 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab/ Exemestane/ Leuprolide
Description: Dose level 1 (Pembrolizumab 150 mg IV Q2W); Dose level -1 (Pembrolizumab 100 mg IV Q2W); Dose level -2 (Pembrolizumab 50 mg IV Q2W) Combination with Exemestane 25 mg PO QD, and Leuprolide 3.75 mg SC Q4W
Study NCT00536471 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01347242 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Autologous CD34 positive cells transduced with a lentiviral vector containing human WAS gene
Description: transplantation of patient's autologous CD34+ cells transduced with lentiviral vector containing human WAS gene
Study NCT03616353 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Perineural Hydrodissection
Description: The subcutaneous tissues of the ulnar aspect of the wrist at the level of the carpal tunnel will be infiltrated with 2 ml of lidocaine 1% for local anesthetic. Using ultrasound guidance and aseptic technique, the needle will then be angled deep to the median nerve within the carpal tunnel, and 5 ml of a 50%/50% mixture of lidocaine 1% and sensorcaine 0.5% will be injected under pressure. While continuing to use ultrasound guidance and aseptic technique, the needle will then be angled superficial to the median nerve within the carpal tunnel, and 5 ml of a 50%/50% mixture of lidocaine 1% and sensorcaine 0.5% will be injected under pressure. The needle will be returned to its original angle deep to the median nerve, and the syringe will be changed to inject 40 mg Depo-Medrol in 1ml of saline.
Study NCT03616353 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Corticosteroid Injection
Description: The subcutaneous soft tissues of the ulnar aspect of the wrist at the level of the carpal tunnel will be infiltrated with 2 ml of lidocaine 1% for local anesthetic. Using ultrasound guidance and aseptic technique, the needle will then be angled deep to the median nerve within the carpal tunnel, and 40 mg Depo-Medrol in 1ml of saline will be injected into the area deep to the median nerve.
Study NCT01102426 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Plitidepsin
Description: plitidepsin: powder and solvent for concentrate for solution for infusion. 2 mg vial + 4 ml ampoule. 5 mg/m2 intravenously (i.v.) over three hours on Day 1 and 15 every 4 weeks. dexamethasone: 4 mg tablet. 40 mg orally on Day 1, 8, 15 and 22 every four weeks at least one hour before plitidepsin infusion.
Study NCT01102426 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: 4 mg tablet. 40 mg orally on Day 1, 8, 15 and 22 every four weeks.
Study NCT01102426 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: 4 mg tablet. 40 mg orally on Day 1, 8, 15 and 22 every four weeks.
Study NCT03248076 — intervention group
Intervention type: DRUG
Intervention: Fentanyl Citrate
Description: 1γ/Kg fentanyl
Study NCT01706055 — intervention group
Intervention type: BIOLOGICAL
Intervention: Interferon beta-1b (Betaseron, BAY86-5046)
Description: Subcutaneous injections of Betaferon 250 mcg every other day according to Product Characteristic.
Study NCT03845647 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: contralateral central lymph node dissection
Description: contralateral central lymph node dissection
Study NCT01295957 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: reminiscence therapy
Description: 24 bi-weekly sessions of reminiscence therapy, lasting one hour each one, over a period of 12 weeks. The latter refers to the use of images, sentences or memorabilia which help to focus on specific segments of the life history of an individual, and stimulates the emergence of affect-laden personal recalls, which are later verbalized in the context of guided conversations12. The term story life is intended to highlight samples of meaningful events of the subject's life rather than a historically structured biography13. Three main variables contributed to reminiscing: individuality, evaluation and structure.
Study NCT01295957 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: comparison group
Description: The control group was administered counseling and informal social contacts in bi-weekly sessions of one hour, common subjects addressed by comparison group were social security incomes, diets, family visits.
Study NCT01295957 — intervention group
Intervention type: OTHER
Group type: NO_INTERVENTION
Intervention: control
Description: advise and informal counseling
Study NCT04359160 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Orthense, Orthense, Digikare Inc. Blagnac, France
Description: Mobile-app follow-up care, with questions and score
Study NCT04359160 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire
Description: Paper questionnaire follow-up, with questions and score
Study NCT00871494 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azithromycin
Description: The patients will receive 500 mg intravenous azithromycin QD for 1 to 2 days. The period of administration of intravenous dosing is judged by investigators according to patient status. Following intravenous administration, the patients will be received the 250 mg oral azithromycin (tablet formulation) QD to complete a total of 7 days therapy.
Study NCT02755909 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Pre-anesthetic Education
Description: Education was done before the anesthetic procedure, using a flip chart made by the researchers.
Study NCT03636295 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Warfarin
Description: Participants in both arms will be on warfarin therapy post-mechanical valve replacement as is standard, but will have different INR target ranges.
Study NCT03636295 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Warfarin
Description: Participants in both arms will be on warfarin therapy post-mechanical valve replacement as is standard, but will have different INR target ranges.
Study NCT02271841 — intervention group
Intervention type: DEVICE
Intervention: PVI
Description: Pleth Variability Index
Study NCT04769219 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Secondary prevention training
Description: Secondary prevention training will be given after acute myocardial infarction
Study NCT01970683 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: VSL #3 BID
Study NCT01970683 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: VSL #3 BID
Study NCT00062478 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Karenitecin (BNP1350)
Description: Karenitecin 1.0 mg/m2 administered as a single 60-minute IV infusion daily for five consecutive days. The cycle is repeated every 21 days until occurrence of progressive disease or unacceptable toxicity.
Study NCT02975609 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Fractionated Radiotherapy
Description: 5Fx/W,3Gy/Fx,Dt:PTV-G:30Gy/10F/2W for metastatic sites, Dt:60Gy/30F for primary tumor and metastatic lymph node.
Study NCT00830466 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Laser and rapamycin versus laser alone
Description: Laser and rapamycin versus laser alone
Study NCT02975609 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiation Therapy
Description: 30Gy/3-5F for the primary and the metastases.
Study NCT02152761 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bimagrumab
Description: Bimagrumab was administered as intravenous infusion starting on Day 1 until week 20.
Study NCT04098458 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: NDURE
Description: NDURE consists of 6 key functions including (1) Improve patient knowledge about guidelines for timely PORT and associated care processes; (2) Minimize the burden of travel for HNSCC care; (3) Improve communication between patients and providers regarding intentions and goals for timely, guideline-adherent PORT; (4) Enhance coordination of care between healthcare teams during care transitions and about treatment sequelae; (5) Track referrals to ensure timely scheduling of appointments and patient attendance across fragmented healthcare systems; (6) Restructure the organization to clarify roles and responsibilities for care processes associated with PORT delivery to avoid duplication and gaps in care. Direct contact between the NDURE navigator and patient occurs via three clinic-based, face-to-face NDURE sessions lasting 30-60 minutes each at the pre-surgical consult, hospital discharge, and first postoperative visit.
Study NCT03189628 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: stromal vascular fraction
Description: The adipose tissue(no less than 40ml) in abdomen will be harvested and digested at 37 °C for (45-60) min with (0.125-1.5)mg/ml collagenase . After filtration and centrifugation at the speed of (700-1500)g, mature adipocytes are separated from the cell pellet. The pellet then is treated with saline twice to remove cell fragment and rudimental collagenase . The harvested pellet is stromal vascular fraction (SVF) The SVF was resuspended in 1 ml saline and transplanted for 3 area including the forehead、palpebra inferior and crow's-feet.
Study NCT03189628 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: 1 ml saline was injected for 3 area including the forehead、palpebra inferior and crow's-feet.
Study NCT03143283 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Safety Study Lethal Means Counseling
Description: Clinicians provide applicable families with locking devices and handouts on safe storage of firearms and medications.
Study NCT04855968 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: In addition to standard post-op medication patient will have access to the head space meditation application.
Description: Patients will receive access to head space meditation application in addition to standard pain medication post surgery.
Study NCT02845752 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Stiolto Respimat
Description: Oral inhalation spray
Study NCT02845752 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Stiolto Respimat
Description: Oral inhalation spray
Study NCT04855968 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Patients will take standard post-op pain medication
Description: Standard post-op pain medication
Study NCT03203967 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Epidural morphine
Description: 2 mg of morphine (0.4 mg/ml morphine in 5 ml normal saline) is administered through the epidural catheter at the end of surgery.
Study NCT03203967 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Epidural placebo
Description: 5 ml normal saline is administered through the epidural catheter at the end of surgery.
Study NCT03203967 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Single femoral nerve block
Description: Single femoral nerve block is performed with 20 ml 0.5% ropivacaine under the guidance of ultrasonography and nerve stimulator after surgery.